Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Katia M.C. Verhamme, Catherine Lucet, Alain Van Meerhaeghe, Guy G.O. Brusselle, Marie-Laurence Lambert. Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018

Member's Comments

No comment yet.

Related content which might interest you: Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Short term improvement of asthma control by omalizumab in difficult-to-treat asthmatic children: A French national survey Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Adherence to beclomethasone in children with persistent asthma in a low-income country: a randomized concurrent cohort study Source: Eur Respir J 2005; 26: Suppl. 49, 162s Year: 2005 Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006–2016 Source: Eur Respir J, 53 (4) 1802130; 10.1183/13993003.02130-2018 Year: 2019 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Sub-optimal asthma control with medium- or high-dose ICS/LABA: a retrospective cohort study from Japan claims database Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 One year of mepolizumab in severe asthma in Italy: efficacy and safety Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Anti-inflammatory asthma therapy adherence in paediatric patients: The PACMAN cohort study Source: Annual Congress 2010 - Management of airway disease Year: 2010